Advertisements

Junel Fe 1.5 / 30

Quick links to important sections

Junel Fe 1.5 / 30

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Junel Fe 1.5 / 30

Quick Facts

Property Description
Active ingredients Norethindrone Acetate, Ethinyl Estradiol, Ferrous Fumarate (inert)
Form Oral Tablet
Pharmacological class Combined Oral Contraceptive (COC)
Common use Pregnancy Prevention
Origin Synthetic Hormonal Steroids

What Type of Medication is Junel Fe 1.5 / 30?

Junel Fe 1.5 / 30 is classified as a Combined Oral Contraceptive (COC), a prescription-only, synthetic medication whose primary and clinically recognized purpose is pregnancy prevention. The drug entity is a systemic therapy administered as an oral tablet, and it belongs to the pharmacological class of estrogen and progestin combinations. This specific combination of hormones is used for controlling fertility in women of reproductive age. This COC classification indicates that the formulation requires the integration of two distinct classes of active synthetic hormone components to achieve its therapeutic effect: a Progestin (Norethindrone Acetate) and an Estrogen (Ethinyl Estradiol).

Composition: Active Ingredients and Monophasic Form

The core composition of this combination product centers on its two active ingredients, Norethindrone Acetate and Ethinyl Estradiol. The formulation is structured as a monophasic oral contraceptive, meaning the amount of both the Norethindrone (Progestin) and the Ethinyl Estradiol (Estrogen) is fixed and remains consistent throughout the 21 hormonally active tablets. This consistent, monophasic delivery is a key feature, differentiating it from multiphasic products which vary hormone ratios across the cycle. The designation "Fe" in Junel Fe 1.5 / 30 indicates the presence of Ferrous Fumarate within the seven non-hormonal, or inert, tablets included in the 28-day regimen. There is a distinction between the active hormonal components and the inert Ferrous Fumarate in the final seven tablets of the preparation. The Ferrous Fumarate component is non-contraceptive and functions solely to maintain patient adherence to the continuous schedule.

Regulatory References

  1. National Library of Medicine (NIH)
Advertisements

What side effects are possible with Junel Fe 1.5 / 30?

Possible Side Effects and Safety Information

The official safety profile for Junel Fe 1.5 / 30, a combined oral contraceptive (COC), documents possible adverse reactions classified by frequency and body system, strictly according to regulatory standards.

Common and System-Specific Adverse Reactions

Adverse reactions frequently reported by users in official regulatory documents often affect multiple physiological systems. Common effects, reported by a significant percentage of users, typically include headache, nausea, breast tenderness, and irregular uterine bleeding (spotting or breakthrough bleeding). Other documented effects are grouped by System-Organ-Classes (SOCs) and involve Gastrointestinal disorders (vomiting, abdominal pain), Nervous system disorders (migraine), and Psychiatric disorders (mood changes, depression).

Serious Adverse Reactions and Safety Constraints

Regulatory agencies emphasize that all COCs are associated with a rare but serious risk of thromboembolic disorders. These Serious Adverse Reactions include the potential for Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, and Myocardial Infarction. The risk of these events is significantly increased for women over age 35 who smoke, a key Population-Specific Safety Consideration that acts as a strong restriction on use. Additionally, the medication is contraindicated in individuals with a history of these thrombotic diseases or with severe liver conditions, such as Hepatic Neoplasia.

Irregular bleeding is most commonly reported as an Exposure-Related Pattern during the first few months of therapy. The formal documentation of these risks and constraints provides the complete regulatory assessment of the drug’s safety profile.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for overdose of combined oral contraceptives (containing Norethindrone Acetate and Ethinyl Estradiol) defines the expected manifestations and the required emergency response.

Documented Overdose Manifestations

Element Official Regulatory Statements
Hormonal Overdose Symptoms Nausea, Vomiting, and Withdrawal Bleeding are the most common signs cited in regulatory reports.
Hormonal Severity Overdose of the active hormonal components is generally classified as non-serious; serious ill effects have not been reported in children following acute ingestion of hormones.
Iron Component Risk The presence of Ferrous Fumarate (iron) introduces a severe risk domain, as accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under six years old.

Official Emergency Actions

Action Regulator-Mandated Procedure
Immediate Action Required Seek immediate medical attention for any suspected overdose. Contact a Poison Control Center right away.
Antidote and Treatment No specific antidote is known for the hormonal components. Treatment is limited to symptomatic and supportive treatment.

The dual-risk structure of the product necessitates that an individual seek urgent medical help immediately upon suspicion of overdose, primarily due to the severe, potentially fatal risk associated with the iron component, even if the hormonal symptoms appear mild.

Advertisements

Therapeutic Uses of Junel Fe 1.5 / 30

What Junel Fe 1.5/30 Treats: Main Uses and Benefits

The primary therapeutic goal of Junel Fe 1.5/30 is to support pregnancy prevention, offering women of reproductive age a widely recognized method for long-term fertility control. This medication addresses the continuous need for planned reproductive health management. Beyond its primary role, this combination pill is also commonly applied in contexts where additional symptomatic support is needed, and is applied in addressing distressing manifestations like excessive menstrual blood loss, pronounced painful periods, and moderate acne.

In clinical scenarios, it is relevant for supporting menstrual regularity and contributes to easing the overall symptom burden. This is commonly used to help address symptom clusters that interfere with daily functioning. Additionally, the ancillary inclusion of ferrous fumarate provides a supportive benefit by offering supplemental iron to mitigate the symptomatic burden associated with potential iron depletion from regular monthly flow. This assists with maintaining functional stability.

Quick Fact: Relief for Symptom Clusters
Menstrual Distress Contributes to improved comfort and may assist with managing symptoms like heavy flow and painful cramping.
Moderate Acne Is relevant for easing symptoms related to inflammatory or irritative states.

Regulatory References

  1. JUNEL FE 1.5/30 Official Labeling - DailyMed, NIH
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Junel Fe 1.5 / 30?

Junel Fe 1.5 / 30 is officially approved for use in females of reproductive age who have begun menstruation (post-menarche). The regulatory labeling strictly defines several populations for whom use is prohibited, primarily due to the increased risk of serious adverse vascular events.


Contraindications: Populations That Must Not Use

Use is absolutely contraindicated by regulatory authorities in women with specific pre-existing health issues, including:

  • Cardiovascular and Thrombotic Risk: Individuals over 35 years old who smoke, or those with a history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), stroke, or uncontrolled hypertension.
  • Hepatic and Endocrine Conditions: Women with active liver disease, liver tumors, or a history of jaundice from previous oral contraceptive use.
  • Malignancy Risk: Individuals with breast cancer or other estrogen-dependent neoplasia, as well as those with undiagnosed abnormal uterine bleeding.

Age and Physiological Restrictions

Category Regulatory Status
Pediatric Use Indicated only after menarche (onset of menstruation).
Geriatric Use Not indicated for postmenopausal women; use is not established.
Pregnancy Contraindicated; stop use if pregnancy is confirmed.
Lactation Not recommended in the immediate postpartum period or while actively breastfeeding.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The effectiveness of this product can be affected by other medicines, which may increase or decrease the levels of the contraceptive hormones (norethindrone and ethinyl estradiol) in the body.

Impact of Other Medicines on Hormone Levels

  • Enzyme Inducers: Medicines that induce certain liver enzymes, such as CYP3A4 inducers (e.g., rifampin, barbiturates, phenytoin, carbamazepine, St. John's Wort), may significantly decrease the plasma concentrations of the hormones. This can lead to a risk of reduced contraceptive effectiveness and increased breakthrough bleeding. An alternative or back-up method of contraception is typically required during and for a period after stopping the inducer.
  • Enzyme Inhibitors: Medicines and products that inhibit certain enzymes, such as CYP3A4 inhibitors (e.g., certain azole antifungals, grapefruit juice), or inhibit hormone conjugation (e.g., ascorbic acid, acetaminophen) may increase the plasma concentrations of the hormones.

Impact on Co-administered Medicines

  • Other Substrates: This product may affect the levels of other co-administered drugs that are substrates for metabolizing enzymes. For example, it can decrease the plasma concentrations of lamotrigine.
  • Iron Component Interference: The iron component (ferrous fumarate) in the inactive tablets can reduce the absorption of certain orally co-administered drugs, such as bisphosphonates and thyroid hormone replacements (e.g., levothyroxine). These medicines should be spaced at least four hours apart from the iron tablets.

Contraindicated Combinations

Co-administration with Hepatitis C drug regimens containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, is contraindicated due to the potential for significant increases in ALT (liver enzyme) levels.

Advertisements

Mechanism of Action

The mechanism of action of Junel Fe 1.5 / 30 is defined by the pharmacodynamic activity of norethindrone acetate (a synthetic progestin) and ethinyl estradiol (an estrogen component). These exogenous steroids primarily exert a negative feedback effect on the hypothalamic-pituitary-ovarian (HPO) axis.

This negative feedback suppresses the pulsatile secretion of Gonadotropin-Releasing Hormone (GnRH), which, in turn, inhibits the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) from the anterior pituitary gland. The resulting suppression of the mid-cycle LH surge prevents follicular maturation and subsequent ovarian follicle rupture, thereby inhibiting ovulation.

Simultaneously, the progestin component induces biochemical and physical changes in the cervical mucus, significantly increasing its viscosity and reducing its volume. This alteration mechanically impedes sperm motility and transit. Furthermore, the combination modulates the endometrium, causing hypoplasia and atrophy that reduce its thickness and cellular proliferation.

Advertisements

Dosage and Administration Information

Instruction Map: Official Administration Guidelines

Route of administration: Junel Fe 1.5 / 30 is administered orally as one tablet taken by mouth daily. This continuous 28-day regimen is the standard official schedule. The dosage sequence includes 21 days of the active hormonal tablet (Norethindrone Acetate 1.5 mg / Ethinyl Estradiol 30 mcg), followed by 7 days of the inactive tablet containing 75 mg Ferrous Fumarate. Administration may occur without regard to meals.


Frequency and Timing: The central procedural requirement is that the tablet must be taken once daily at the same time every day and in the sequence directed on the blister packaging. This rule, which should be adhered to strictly, is necessary to maintain consistent drug levels throughout the cycle.


Special Procedural Conditions: When initiating the medication, a non-hormonal backup method is required for the first seven days if the first active tablet is taken later than Day 1 of the menstrual cycle. Specific administration rules exist for starting after a first-trimester abortion or miscarriage (may be started immediately) or after giving birth (no earlier than four weeks postpartum for non-breastfeeding women).


Missed-Dose Protocol: If one active tablet is missed, the official guidance is to take the missed tablet as soon as possible and resume the regular schedule. If two or more active tablets are missed consecutively, detailed rules apply, generally requiring both compensatory doses and the temporary use of a backup non-hormonal method for seven days. Missed inactive tablets should be discarded, and the regular schedule resumed.


Procedural Structure Summary: The official instructions establish a continuous, daily use protocol that mandates adherence to a fixed time and a sequential order. This structure ensures a defined 21-day hormonal phase followed by a 7-day non-hormonal phase, defining the use over the long term.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Junel Fe 1.5 / 30

Evidence for Use in Pregnancy Prevention (Contraception)

The primary body of evidence for the active hormonal ingredients in this medication was evaluated in extensive randomized controlled trials (RCTs) and large-scale observational studies. Research examined the fundamental outcome of pregnancy incidence, applying metrics such as the Pearl Index to measure pregnancy incidence when the medication was observed in controlled settings. These studies focused primarily on sexually active women of reproductive age who were healthy or generally healthy and seeking a method of fertility control.

Studies monitored user continuation rates and data show patterns related to pregnancy incidence when the pills was observed in consistent usage. Research also explored outcomes related to menstrual cycle regularity, where findings described patterns related to menstrual cycle regularity in the observed populations. This evidence contributes to the available evidence base for combined oral contraceptives (COCs).

Evidence for Ancillary Uses: Menstrual and Dermatological Symptoms

Studies have explored the potential use of this type of hormonal combination in conditions characterized by fluctuating or episodic manifestations, specifically those linked to menstrual and dermatological health. This research focuses on outcomes reflecting daily functioning or activity level, as well as patient-reported experiences.

Research on Heavy Menstrual Blood Loss and Painful Periods

For conditions associated with acute or disruptive episodes, such as excessive menstrual blood loss, research has examined various outcomes in randomized controlled trials and systematic reviews. Researchers monitored measurements of blood loss volume and tracked changes in hemoglobin levels and related markers. Research describes patterns observed in the measurements of menstrual blood loss volume over several treatment cycles.

Research on Moderate Acne

The use of combined hormonal ingredients was studied for conditions, such as moderate acne. Studies monitored outcomes linked to inflammatory or irritative states, recording lesion counts (inflammatory and non-inflammatory) and overall changes in acne severity scores in female patients post-menarche whose symptoms had not responded fully to standard topical treatments.

What is Still Uncertain About Junel Fe 1.5 / 30 Evidence

Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain. Several limitations apply to the overall evidence base. Sample sizes were modest in some of the older trials, and the evidence quality varies across studies, particularly for the ancillary indications. Follow-up durations were limited in many primary RCTs, meaning the long-term effects are not fully established and rely on external observational data. Finally, comparative evidence is lacking against all possible alternative treatments, meaning that findings describe group patterns, not personal outcomes, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. JUNEL FE 1.5/30 Official Labeling - DailyMed
  2. NIH MedlinePlus Drug Information: Norethindrone Acetate and Ethinyl Estradiol
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Junel Fe 1.5 / 30 (FAQ)


Q: Why does Junel Fe 1.5 / 30 contain iron (Fe)?

The 'Fe' component stands for Ferrous Fumarate, which is an iron-containing ingredient found in the seven non-hormonal (inactive) tablets. This ingredient is included to encourage adherence to the continuous 28-day regimen. According to official documents, the iron component does not have a contraceptive function.


Q: Can taking Junel Fe 1.5 / 30 cause changes in weight?

Official product information documents from regulatory bodies describe that changes in weight are reported by some users during clinical use. Both weight gain and weight decrease have been included in the list of documented adverse reactions.


Q: How long does it typically take for the body to adjust to Junel Fe 1.5 / 30?

Regulatory documents indicate that irregular uterine bleeding, such as spotting or breakthrough bleeding, is most frequently reported during the first few months of starting the therapy. The duration for adjustment to other potential effects is not explicitly defined in the official labeling.


Q: What should be done about missed doses, generally speaking?

The official guidance for a single missed active tablet involves taking the tablet as soon as possible and continuing the regular schedule, but specific instructions should be reviewed in the official labeling. Missing two or more active tablets requires following detailed procedures, which typically involve taking compensatory doses and using a non-hormonal backup method for seven days, as outlined in the official instructions.


Q: Can the effectiveness of Junel Fe 1.5 / 30 be reduced by vomiting or severe diarrhea?

The active ingredients are absorbed in the gastrointestinal tract. Official information indicates that conditions that severely disrupt the normal digestive process, like excessive vomiting or severe diarrhea, may potentially interfere with the proper absorption of the hormones. This could result in lower levels of the drug in the blood.


Q: Are there any dietary restrictions mentioned in the official instructions for Junel Fe 1.5 / 30?

Official instructions specify a documented interaction with grapefruit juice. Grapefruit juice may inhibit the enzymes that process the hormones in the body, which could potentially lead to increased concentrations of the active ingredients in the bloodstream.


Q: How does Junel Fe 1.5 / 30 compare to other combination birth control pills?

Junel Fe 1.5 / 30 is classified as a monophasic combination oral contraceptive (COC). It contains a dose of 1.5 mg of the progestin norethindrone acetate and 30 mcg of the estrogen ethinyl estradiol, which places it within the range of hormone amounts typically found in many prescribed oral contraceptives.


Q: What is the difference between Junel Fe 1.5 / 30 and Junel Fe 1 / 20?

The official difference is in the amount of active ingredients. Junel Fe 1.5 / 30 has 1.5 mg of the progestin and 30 mcg of the estrogen, while Junel Fe 1 / 20 contains 1 mg of the progestin and 20 mcg of the estrogen.


Q: Does Junel Fe 1.5 / 30 affect acne?

Combination oral contraceptives with similar hormonal compositions are formally indicated by regulatory agencies for the treatment of moderate acne vulgaris. Official indications for this type of medication state that it is used in females who have achieved menarche and who desire oral contraception.


Q: Are there any over-the-counter supplements that interact with Junel Fe 1.5 / 30?

Official drug labels list the herbal supplement St. John's Wort as an ingredient that may significantly reduce the plasma concentrations of the contraceptive hormones. This interaction could potentially lead to a reduction in the drug's effectiveness.


Q: Can Junel Fe 1.5 / 30 be used by people who have never given birth?

Yes, official documents state the medication is indicated for use by females of reproductive potential to prevent pregnancy. There are no restrictions in the regulatory labeling based on a history of having given birth.


Q: Is Junel Fe 1.5 / 30 effective immediately after starting the first pack?

Official instructions specify that maximum contraceptive effect may not be achieved until after the first seven consecutive days of active pill use. If a person does not start on the first day of their menstrual cycle, a non-hormonal backup method is recommended for the first seven days.


Q: What happens if a person needs to stop taking Junel Fe 1.5 / 30?

When the medication is discontinued, the contraceptive effect is stopped. Official documents note that if pregnancy is confirmed, the product should be discontinued immediately. The return of ovulation and fertility levels similar to pre-treatment states are generally observed following cessation of the medication.


Q: Does Junel Fe 1.5 / 30 affect hair loss or hair growth?

Postmarketing reports cited in official safety documents have included both alopecia (hair loss) and hirsutism (increased or unwanted hair growth) as documented adverse reactions reported by some users.


Q: Is Junel Fe 1.5 / 30 gluten-free or lactose-free?

According to the official product description, the tablet formulation contains lactose monohydrate as an inactive ingredient. The product is not specifically labeled or characterized as gluten-free in regulatory information.


Q: What type of progesterone is used in Junel Fe 1.5 / 30?

The progestin component in the medication is norethindrone acetate. This is a synthetic hormone that is pharmacologically derived from 19 -nortestosterone, which is a classification often referred to as a first-generation progestin.


Q: Can certain herbal products interact with the effectiveness of Junel Fe 1.5 / 30?

Yes, the herbal product St. John's Wort is specifically mentioned in official documents. This product may decrease the concentration of the hormones in the blood by speeding up their metabolism, potentially reducing the contraceptive effectiveness of the pill.


Q: Does Junel Fe 1.5 / 30 have a generic equivalent?

Yes, the formulation containing 1.5 mg of norethindrone acetate and 30 mcg of ethinyl estradiol is available under multiple generic names. Regulatory authorities consider these to be therapeutically equivalent to the brand name product.


Q: Can Junel Fe 1.5 / 30 be used to skip periods?

The official product labeling is based on a standard 28-day regimen that includes 7 non-hormonal tablets. Decisions about adjusting the pill-taking schedule for continuous use or to minimize bleeding should align with the official prescribing information.


Q: Are there any eye-related side effects associated with Junel Fe 1.5 / 30?

Official safety documents describe that combined oral contraceptive use has been associated with rare cases of retinal thrombosis (a clot in the eye's blood vessels), which may potentially lead to a partial or complete loss of vision. Some users may also report visual changes or issues with contact lens tolerance.


Q: What is the general relationship between Junel Fe 1.5 / 30 and migraine headaches?

Migraines are listed as a possible adverse reaction in the safety profile. Importantly, the product is absolutely contraindicated (must not be used) in women who experience migraines accompanied by focal neurological symptoms or migraine with aura due to an increased risk of stroke.


Q: Does Junel Fe 1.5 / 30 affect cholesterol levels?

Official warnings note that certain progestins may potentially affect lipid levels, and regulatory bodies recommend that women with high cholesterol (hyperlipidemia) be monitored carefully.


Q: Is there a link between Junel Fe 1.5 / 30 and changes in libido?

Postmarketing reports submitted to regulatory agencies have included changes in libido (interest in sex) as an adverse reaction reported by some users of the medication.


Q: Does the time of day a person takes Junel Fe 1.5 / 30 matter?

Yes, official instructions emphasize that the active tablet must be taken once daily at the same time every day. This consistent timing is crucial to maintain steady hormone levels in the body, which is required for ensuring contraceptive effectiveness.


Q: Are there any documented interactions with grapefruit or grapefruit juice?

Yes, grapefruit juice is listed in official regulatory documents as having a moderate interaction. It may cause an increase in the plasma concentrations of the contraceptive hormones by inhibiting certain metabolizing enzymes.


Q: Is it normal to experience breast tenderness with Junel Fe 1.5 / 30?

Yes, official safety documents describe breast tenderness or breast pain as a common adverse reaction. This is frequently reported by users of combined oral contraceptives.


Q: Can certain herbal teas reduce the effectiveness of Junel Fe 1.5 / 30?

Official drug documents specifically mention that the herbal product St. John's Wort, which is sometimes used in teas or supplements, acts as an enzyme inducer. This action can significantly reduce the concentration of the hormones in the blood and potentially reduce the effectiveness of the medication.


Q: What evidence exists regarding the use of Junel Fe 1.5 / 30 for treating conditions other than birth control?

Beyond pregnancy prevention, combined oral contraceptives are formally indicated by regulatory authorities for the treatment of moderate acne vulgaris. Official research has also examined the impact of this type of hormonal combination on conditions like excessive menstrual blood loss.

Advertisements

How should Junel Fe 1.5 / 30 be stored and disposed of?

The official requirements for Junel Fe 1.5/30 specify the required storage environment and disposal procedures.

Storage Conditions and Safety

The medication must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Short-term temperature excursions are permitted between 15 C and 30 C. The product must be kept in its original container in a cool, dry place to protect it from moisture.

A mandatory safety requirement is to keep Junel Fe 1.5/30 out of the sight and reach of children and pets. This caution is critical because the presence of Ferrous Fumarate (iron) makes accidental overdose a leading cause of fatal poisoning in young children.

Disposal Instructions

Unused or expired product must be properly discarded and is not to be flushed down a toilet or poured down a drain unless specifically instructed. The recommended method for disposal is utilizing a drug take-back program or consulting a pharmacist for guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Junel Fe 1.5 / 30 found in:

A-Z Index: